Ac Immune Sa

Genentech, Inc.

Nestec S.a.

Katholieke Universiteit Leuven

The United States of America As Represented by the Department of Health

Janssen Pharmaceuticals, Inc.

Other

The United States of America As Represented by the Secretary of

Genetech, Inc.

Nestac S.a.

Katholieke Universiteit Leuven, K.u. Leuven Research & Development

Andrea M Pfeifer

Andreas Muhs

Maria Pihlgren

Ryan Jefferson Watts

Oskar Adolfsson

Fred Van Leuven

Curtis C Harris

Frank J Gonzalez

Harry V Gelboin

Maria Pihlgren Bosch

Claude Nicolau

Yvonne Tromvoukis

St&eacute;phanie Blum

David T Hickman

Wolfgang Froestl

Heiko Kroth

Marija Vukicevic Verhille

Nicolas Piot

Elizabeth Anne Ramsburg

Saroj Raj Ghimire

Donata De Marco

Charlotte Sadaka

Katharine C Mace

Freddy Kamiel Van Leuven

Florence Rochat

Isidro Hotzel

Ruth Greferath

Karlheinz Bortlik

Markus Baur

John F Lechner

Myriam Richelle

Pierre Lambelet

Gai Ayalon

Danielle Marie Di Cara

Corinne Lesens

Roger R Reddel

Katherine Mace

Francoise Saucy

Katharine H Cole

Eliane Duruz

Christian Darimont

Pedro Reis

Rime Madani

William Charles Mobley

Pavel Vasilyevich Belichenko

David Hickman

Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.

Method of safe administration of phosphorylated Tau peptide vaccine

Method of safe administration of phosphorylated tau peptide vaccine

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).

Methods of diagnosing tau-protein-associated disease

Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system

The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.

Method for preparing liposome-based constructs

The present invention provides methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).

Humanized tau antibody

The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same.

Anti-tau antibodies and methods of use

The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Polynucleotides encoding anti-amyloid beta monoclonal antibodies

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).

Phosphospecific antibodies recognising tau

The present invention provides methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of amyloid-beta proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.

Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody

Pharmaceutical composition

The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.

Methods for identifying safe and functional humanized antibodies

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of &#x3b2;-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Monoclonal antibody

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of &#x3b2;-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).

Polynucleotides encoding an anti-beta-amyloid monoclonal antibody

Growing community of inventors

Vevey, Switzerland

Andrea M Pfeifer